We also demonstrated the potential efficacy of combining p53 activators with elesclomol-Cu to significantly suppress tumor growth, thereby providing a novel therapeutic strategy with potential clinical applications in the treatment of HCC. This evidence concerns the gene TP53 and neoplasm.